- Home
- IMAB vs EPIX Comparison
IMAB vs EPIX Comparison
Compare IMAB & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- EPIX
- Stock Information
- Founded
- IMAB 2014
- EPIX 2009
- Country
- IMAB United States
- EPIX Canada
- Employees
- IMAB N/A
- EPIX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- EPIX Health Care
- Exchange
- IMAB Nasdaq
- EPIX Nasdaq
- Market Cap
- IMAB 79.9M
- EPIX 76.8M
- IPO Year
- IMAB 2020
- EPIX N/A
- Fundamental
- Price
- IMAB $0.84
- EPIX $1.63
- Analyst Decision
- IMAB Strong Buy
- EPIX Hold
- Analyst Count
- IMAB 3
- EPIX 3
- Target Price
- IMAB $8.00
- EPIX $2.00
- AVG Volume (30 Days)
- IMAB 216.1K
- EPIX 172.2K
- Earning Date
- IMAB 03-21-2025
- EPIX 02-11-2025
- Dividend Yield
- IMAB N/A
- EPIX N/A
- EPS Growth
- IMAB N/A
- EPIX N/A
- EPS
- IMAB N/A
- EPIX N/A
- Revenue
- IMAB $569,464.00
- EPIX N/A
- Revenue This Year
- IMAB N/A
- EPIX N/A
- Revenue Next Year
- IMAB N/A
- EPIX N/A
- P/E Ratio
- IMAB N/A
- EPIX N/A
- Revenue Growth
- IMAB N/A
- EPIX N/A
- 52 Week Low
- IMAB $0.76
- EPIX $1.40
- 52 Week High
- IMAB $2.00
- EPIX $9.60
- Technical
- Relative Strength Index (RSI)
- IMAB 38.53
- EPIX 40.19
- Support Level
- IMAB $0.78
- EPIX $1.62
- Resistance Level
- IMAB $0.93
- EPIX $1.70
- Average True Range (ATR)
- IMAB 0.07
- EPIX 0.05
- MACD
- IMAB -0.01
- EPIX -0.00
- Stochastic Oscillator
- IMAB 33.45
- EPIX 20.00
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.